Mark Angelino PhD

Dr. Angelino is SVP of Pharmaceutical Sciences at bluebird bio. He manages the development, analytical development/QC, and clinical manufacturing functions for both our lentiviral vector materials and autologous drug products. He was most recently at Baxter Healthcare for which he led their Cambridge, MA R&D site.

His experience spans the regulated environment from development through commercialization including lead roles on validation of Integrilin, validation and commercial supply chain for generic enoxaparin (Lovenox), and the ANDA submission for generic Copaxone. He has worked on small-molecule, peptide, biologic, bioconjugate, oligonucleotide, and complex mixture development programs through various companies including Momenta Pharmaceuticals, Millennium Pharmaceuticals, and Bristol-Myers Squibb.